These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37349237)

  • 1. Peripheral blood mononuclear cell- transcriptome signatures of atopic dermatitis and prediction for the efficacy of dupilumab.
    Wang Y; Wu Y; Gu C; Wang S; Yin H; Zhu R; Wang C; Li Z; Yao X; Li W
    J Dermatol Sci; 2023 Sep; 111(3):83-92. PubMed ID: 37349237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
    Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
    J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
    Hamilton JD; Suárez-Fariñas M; Dhingra N; Cardinale I; Li X; Kostic A; Ming JE; Radin AR; Krueger JG; Graham N; Yancopoulos GD; Pirozzi G; Guttman-Yassky E
    J Allergy Clin Immunol; 2014 Dec; 134(6):1293-1300. PubMed ID: 25482871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Wu Y; Gu C; Wang S; Yin H; Qiu Z; Luo Y; Li Z; Wang C; Yao X; Li W
    Br J Dermatol; 2023 Apr; 188(5):649-660. PubMed ID: 36756674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senescent fibroblasts and innate immune cell activation might play a role in the pathogenesis of elderly atopic dermatitis.
    Luo Y; Fang X; Zhou Y; Zhang Y; Li W; Leng SX; Yao X; Liu X
    J Dermatol Sci; 2024 Jun; 114(3):94-103. PubMed ID: 38806324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atopic dermatitis displays stable and dynamic skin transcriptome signatures.
    Möbus L; Rodriguez E; Harder I; Stölzl D; Boraczynski N; Gerdes S; Kleinheinz A; Abraham S; Heratizadeh A; Handrick C; Haufe E; Werfel T; Schmitt J; Weidinger S;
    J Allergy Clin Immunol; 2021 Jan; 147(1):213-223. PubMed ID: 32615169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
    Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
    Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
    Gu C; Wu Y; Luo Y; Wang S; Yin H; Gao Y; Wang C; Yao X; Li W
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1064-1073. PubMed ID: 35344634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis.
    Möbus L; Rodriguez E; Harder I; Boraczynski N; Szymczak S; Hübenthal M; Stölzl D; Gerdes S; Kleinheinz A; Abraham S; Heratizadeh A; Handrick C; Haufe E; Werfel T; Schmitt J; Weidinger S;
    J Allergy Clin Immunol; 2022 Aug; 150(2):385-395. PubMed ID: 35182548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis.
    Möbus L; Rodriguez E; Harder I; Schwarz A; Wehkamp U; Stölzl D; Boraczynski N; Gerdes S; Litman T; Kleinheinz A; Abraham S; Heratizadeh A; Handrick C; Haufe E; Schmitt J; Werfel T; Weidinger S;
    J Allergy Clin Immunol; 2021 May; 147(5):1959-1965.e2. PubMed ID: 33390269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.